BioReference will offer COVID-19 testing for public drive-through facilities for Miami residents and Larkin Community Hospital
ELMWOOD PARK, N.J., March 24, 2020 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a collaboration with the City of Miami to provide coronavirus disease 2019 (COVID-19) testing. BioReference will provide COVID-19 testing at drive-through locations for Miami residents by appointment.
BioReference is also announcing that they are providing testing for drive-through testing centers in South Florida, Hialeah and Hollywood through a collaboration with Larkin Community Hospital.
“We all are responsible for helping to control the spread of this virus,” said Francis Suarez, Mayor of the City of Miami. “As an individual who tested positive for COVID-19, I have a duty to the City of Miami to bring my city’s residents access to testing and information, and through our partnership with BioReference, we can help address this public health crisis.”
“BioReference continues to prioritize expanding public access to COVID-19 testing across the nation,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. “The importance of high-quality, reliable, scalable laboratory tests available is a critical part of the response in the effort to contain COVID-19.”
If you demonstrate symptoms related with COVID-19, please call the Florida Department of Health immediately: 1-866-779-6121 or call the City of Miami COVID-19 Center: 1-305-960-5027.
Providers should refer to the most current CDC guidelines for further information on appropriate testing of patients, available here https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html.
About COVID-19 Testing at BioReference Laboratories, Inc.
BioReference Laboratories is accepting specimens for COVID-19 testing from healthcare providers, clinics and health systems throughout the United States to promote earlier diagnosis of the coronavirus and to aid in limiting spread of infection. In addition to its nationwide COVID-19 testing offering, BioReference has partnerships with the New York State Department of Health, the New York City Health and Hospital Corporation (NYC Health + Hospitals), the State of New Jersey and the City of Detroit to provide COVID-19 testing.
BioReference is offering a real-time reverse-transcription polymerase chain reaction (real-time RT-PCR) assay with expected 24-48 hour turnaround time. The Novel Coronavirus COVID-19 test has been made available pursuant to the U.S. Food and Drug Administration Emergency Use Authorization for diagnostic testing in CLIA certified high-complexity laboratories. All tests are conducted in BioReference’s main laboratory in Elmwood Park, N.J., which currently has a capacity to run up to 15,000 COVID-19 tests per day. For more information, visit https://www.bioreference.com/coronavirus.
About BioReference Laboratories, Inc.
BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions and medical groups. The company is in network with the five largest health plans in the United States, operates a network of 10 laboratory locations, and is backed by a medical staff of more than 160 MD, PhD and other professional level clinicians and scientists. For more information, visit www.bioreference.com.
About OPKO Health
OPKO Health is a diversified healthcare company. In diagnostics, its BioReference Laboratories is one of the nation’s largest full-service clinical laboratories; GeneDx is a rapidly growing genetic testing business; the 4Kscore® test is used to assess a patient’s individual risk for aggressive prostate cancer following an elevated PSA and to help decide about next steps such as prostate biopsy; Claros® 1 is a point-of-care diagnostics platform with a total PSA test approved by the FDA. In our pharmaceutical pipeline, RAYALDEE is our first pharmaceutical product to be marketed. OPK88003, a once-weekly oxyntomodulin for type 2 diabetes and obesity – reported positive data from a Phase 2 clinical trial. It’s among a new class of GLP-1/glucagon receptor dual agonists. OPK88004, a SARM (selective androgen receptor modulator) is currently being studied for various potential indications. The Company’s most advanced product utilizing its CTP technology, a once-weekly human growth hormone for injection, successfully met its primary endpoint and key secondary endpoints in a Phase 3 study and is partnered with Pfizer. OPKO also has research, development, production and distribution facilities abroad.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains
“forward-looking statements,” as that term is defined under the Private
Securities Litigation Reform Act of 1995 (PSLRA), which statements may be
identified by words such as “expects,” “plans,” “projects,” “will,” “may,”
“anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of
similar meaning, including statements regarding BioReference’s plans to begin
testing for COVID-19 in Miami and the timing of and availability of the test,
the turn-around time for testing and test capacity, as well as other
non-historical statements about our expectations, beliefs or intentions
regarding our business, technologies and products, financial condition,
strategies or prospects. Many factors could cause our actual activities or
results to differ materially from the activities and results anticipated in
forward-looking statements. These factors include those described in the OPKO
Health, Inc. Annual Reports on Form 10-K filed and to be filed with the
Securities and Exchange Commission and in its other filings with the Securities
and Exchange Commission. In addition, forward-looking statements may also be
adversely affected by general market factors, reagent and supply shortages,
competitive product development, product availability, federal and state
regulations and legislation, the regulatory process for new products and
indications, manufacturing issues that may arise, patent positions and
litigation, among other factors. The forward-looking statements contained in
this press release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking statements. We intend
that all forward-looking statements be subject to the safe-harbor provisions of
the PSLRA
Media contacts for BioReference Laboratories:
Hillary Titus, htitus@bioreference.com
